1st Edition
Immune Interferon Properties and Clinical Applications
320 Pages
23 B/W Illustrations
by
CRC Press
320 Pages
by
CRC Press
Also available as eBook on:
Now for the first time, one comprehensive book summarizes and analyzes the numerous scientific papers and reviews covering selected aspects of the structure, biological activities, and clinical effects of immune interferon, also known as interferon-gamma(IFN-gamma). Interferon-gamma is a natural immune booster which has been synthesized and widely used in clinical cases ranging from infectious... Read more
FORWARD
ABBREVIATIONS
THE CYTOKINE FAMILY
INTERFERON GAMMA(IFNg)
Differences Between IFNg and IFN a/b
Interferon-Producing Cells. Inducers and Inhibitors. Effect of Aging
Structure and Physico-Chemical Properties of IFNg
Interferon Gamma Receptors
BIOLOGICAL ACTIVITIES OF INTERFERON GAMMA
Antiviral Activity
Antiproliferative Activity
Immunostimulatory Activity
Modulation of Gene Activity
Antibacterial Activity
Antitumor Activity
MOLECULAR MECHANISMS OF IFNg ACTIVITIES. TRANSMEMBRANE SIGNAL TRANSDUCTION
PRODUCTION OF INTERFERON GAMMA
GAMMA-INTERFERON PREPARATIONS
Interferon Gamma-1b
Gammaferon
Others
INDICATIONS AND CONTRAINDICTIONS
ROUTES OF ADMINISTRATION, PHARMACOKINETICS, DOSAGE
SIDE EFFECTS
INFECTIOUS DISEASES
Viral Infections
Herpes Simplex Type I and Type II
Herpes Zoster
Herpetic and Adenoviral Eye Infections
Respiratory Viral Infections
Human Papilloma Viruses (HPVs)
HIV Infection
Hepatitis
Non-Viral Intracellular Pathogens
Fungi
Non-Viral Extracellular Pathogens
NON-INFECTIOUS NON-MALIGNANT DISEASES
Fibroproliferative Diseases
Atherosclerosis
Multiple Sclerosis (MS)
Psoriasis
Chronic Granulomatous Disease (CGD)
Skin Ulcers in Autoimmune Vasculitis
Rheumatoid Arthritis (RA)
Osteopetrosis
Allergic Disorders
Lupus Erythematosus (SLE)
Heavy Traumas, Burns and Surgical Operations
MALIGNANT DISEASES
Background for Using IFNg in Malignancies
Basocellular Skin Cancer (Basalioma)
Cancer of the Larynx
Lung Cancer
Colorectal Cancer
Malignant Melanoma
Renal Cell Carcinoma (RCC)
Breast Cancer
Cervical Cancer
Gastric Cancer
Prostate Cancer
Ovarian Cancer
Cancer of the Bladder
Hepatocellular Carcinoma (HCC)
Sarcomas
Kaposi's Sarcoma
Neuroblastoma
Gliomas/Glyoblastomas
Hematologic Malignancies
Chronic Myelogenic Leukemia (CML)
B and T Chronic Lymphatic Leukemias (B-CLL and T-CLL)
Acute Leukemias
Lymphomas
Myelodisplastic Syndrome (MDS)
Multiple Myeloma (MM)
Conclusions on the Use of IFN-g In Malignant Diseases
GENERAL CONCLUSIONS
REFERENCES
ABBREVIATIONS
THE CYTOKINE FAMILY
INTERFERON GAMMA(IFNg)
Differences Between IFNg and IFN a/b
Interferon-Producing Cells. Inducers and Inhibitors. Effect of Aging
Structure and Physico-Chemical Properties of IFNg
Interferon Gamma Receptors
BIOLOGICAL ACTIVITIES OF INTERFERON GAMMA
Antiviral Activity
Antiproliferative Activity
Immunostimulatory Activity
Modulation of Gene Activity
Antibacterial Activity
Antitumor Activity
MOLECULAR MECHANISMS OF IFNg ACTIVITIES. TRANSMEMBRANE SIGNAL TRANSDUCTION
PRODUCTION OF INTERFERON GAMMA
GAMMA-INTERFERON PREPARATIONS
Interferon Gamma-1b
Gammaferon
Others
INDICATIONS AND CONTRAINDICTIONS
ROUTES OF ADMINISTRATION, PHARMACOKINETICS, DOSAGE
SIDE EFFECTS
INFECTIOUS DISEASES
Viral Infections
Herpes Simplex Type I and Type II
Herpes Zoster
Herpetic and Adenoviral Eye Infections
Respiratory Viral Infections
Human Papilloma Viruses (HPVs)
HIV Infection
Hepatitis
Non-Viral Intracellular Pathogens
Fungi
Non-Viral Extracellular Pathogens
NON-INFECTIOUS NON-MALIGNANT DISEASES
Fibroproliferative Diseases
Atherosclerosis
Multiple Sclerosis (MS)
Psoriasis
Chronic Granulomatous Disease (CGD)
Skin Ulcers in Autoimmune Vasculitis
Rheumatoid Arthritis (RA)
Osteopetrosis
Allergic Disorders
Lupus Erythematosus (SLE)
Heavy Traumas, Burns and Surgical Operations
MALIGNANT DISEASES
Background for Using IFNg in Malignancies
Basocellular Skin Cancer (Basalioma)
Cancer of the Larynx
Lung Cancer
Colorectal Cancer
Malignant Melanoma
Renal Cell Carcinoma (RCC)
Breast Cancer
Cervical Cancer
Gastric Cancer
Prostate Cancer
Ovarian Cancer
Cancer of the Bladder
Hepatocellular Carcinoma (HCC)
Sarcomas
Kaposi's Sarcoma
Neuroblastoma
Gliomas/Glyoblastomas
Hematologic Malignancies
Chronic Myelogenic Leukemia (CML)
B and T Chronic Lymphatic Leukemias (B-CLL and T-CLL)
Acute Leukemias
Lymphomas
Myelodisplastic Syndrome (MDS)
Multiple Myeloma (MM)
Conclusions on the Use of IFN-g In Malignant Diseases
GENERAL CONCLUSIONS
REFERENCES
Biography
Roumen G. Tsanev, Ivan Ivanov
"…an excellent review of indications studied and under study and the outcomes of IFNg, as well as an exhaustive collection of references for these indications. A briefer overview of the preclinical and pharmacologic aspects of IFNg is provided."
- James E. Talmidge, Ph.D., University of Nebraska Medical School in Doody's Notes
